|
|
|
|
|
-
Monday, December 22, 2025
|
|
 |
|
ACN Newswire能提供全方位的服務。對於希望向媒體、業界和金融市場披露和傳播資訊的公司和組織,我們能為您安排即時的新聞發佈。ACN Newswire的新聞稿包括英文、簡體中文、繁體中文、韓文和日文等多種語言版本。
|
 |
|
|
|
|
| Wednesday, 5 February 2020, 14:17 HKT/SGT | |
| |
|
|
香港, 2020年2月5日 - (亞太商訊) - 關於此次疫情,安捷證券的觀點是:1月23日凌晨武漢封城後的第一波疫情高峰已經到來,並有所緩和。與此同時,隨著返程復工潮的到來,可以預計疫情或將在未來14天內迎來第二波高峰。安捷證券推測第二波高峰的拐點或將出現於2月22日至29日。另一方面,安捷證券認為判斷疫情見頂為之尚早,主要原因是:1) 受制於檢測試劑盒、藥品、床位、醫療耗材等醫療資源超載和診斷物資不足等技術因素,官方的疫情統計數字或只能反映疫情實際情況的一部分;2) 湖北和武漢的實際疫情數據尚不全面,具有較大不確定性;及3) 疫情的區域性集中爆發仍存隱憂。 安捷證券近期選股觀點:建議投資人近期資產配置可以關注疫情相關醫藥股,並以避險資產為主,並密切關注未來14 天疫情變化,建議關注疫情相關的注射劑/藥品/試劑盒/疫苗生產商,如東陽光藥(1558.HK)、麗珠醫藥(1513.HK)、康希諾(6185.HK)等。與此同時,若內地封城、隔離措施持續有效,則14 天后疫情有望發生轉機,安捷證券推測拐點或將出現於2 月22 日至29 日。建議投資者可酌情回歸理性,關注醫藥板塊的長期成長邏輯,長線看好製藥龍頭企業,如中國生物製藥(1177.HK)、石藥集團(1093.HK)、復星醫藥(2196.HK);CRO/CDMO 企業,如藥明生物(2269.HK)、康龍化成(3759.HK);疫苗生產企業,如康希諾(6185.HK),以及嚴重低估的製藥企業,如中國抗體-B(3681.HK)。
話題 Press release summary
部門 金融, 业务
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network
|
|
|
|
|
|
 |
|
Latest Press Releases
Sri Lanka and the Middle East's top real estate achievements recognised at 2025 PropertyGuru Asia Property Awards
Monday, December 22, 2025 9:00:00 AM
|
|
|
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving
Dec 19, 2025, 10:30 HKT/SGT
|
|
|
Air T, Inc. Announces Closing of Regional Express Acquisition
Dec 19, 2025, 06:10 HKT/SGT
|
|
|
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City
Friday, December 19, 2025 2:24:00 AM
|
|
|
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations
Friday, December 19, 2025 2:06:00 AM
|
|
|
Fujitsu to showcase mobility and physical AI tech at CES 2026
Friday, December 19, 2025 1:42:00 AM
|
|
|
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology
Friday, December 19, 2025 1:06:00 AM
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming.
Thursday, December 18, 2025 9:00:00 PM
|
|
|
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM
Dec 18, 2025, 18:09 HKT/SGT
|
|
|
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping
Thursday, December 18, 2025 5:44:00 PM
|
|
|
|
|
More Press release >> |
|
|
|
| Copyright © 2025 ACN Newswire - Asia Corporate News Network |
|
|
頂部 | 關於我們 | 服務 | 合作夥伴 | 聯繫 | 隱私權政策 | 使用條款 | RSS
|
|
|
美國: +1 214 890 4418 | 中國: +86 181 2376 3721 | 香港: +852 8192 4922 | 新加坡: +65 6549 7068 | 東京: +81 3 6859 8575
|
|
|
|
|
| |